Relationship of Periostin and ODI, EQ-5D
Study of Correlation Between Serum Periostin Levels and Oswestry Disability Index and EQ-5D
The intervertebral disc degeneration (IVDD) is a widely recognized musculoskeletal disorder that impose a substantial socioeconomic burden and respresents one of the most important causes of low back pain. IVDD can result from a variety of factors, including aging, obesity, genetic predispositioin, degeneration of of the multifidus and psoas muscles, osteoporosis, inflammation, and oxidative stress.
The IVD consists of a central gelatinous nucleus pulposus (NP), an outer annulus fibrosus (AF), and superior and inferior cartilaginous endplates. The NP and AF produce a water-rich extracellular matrix (ECM), which is essential for normal trunk function.
Dysfunction of the NP and AF, together with excessive metabolic activity of the enplates triggered by various intrinsic and extrinsic stimuli, leads to endplate degeneration and calcification, and ultimately to IVDD. In addition to aging and mechanical overload, increased oxidative stress and pro-inflammatrory cytokine secretion further accelerate the progression of IVDD.
Periostin is an ECM protein which is associated with mechanical stress, inflammation, and aging, and is known to be closely involved in the development and progression of IVDD. Periostin binds to ECM molecule within the IVD and participates in its maintenance and repair; however, excessive ECM turn over drives IVD degeneration and its progression. Periostin influences IVD degeneration through mechanical stress and inflammatory pathways, and serum periostin levels are elevated in patients with severe IVD degeneration. A recent study demonstrated strong corrrelation between serum periostin concentration and the Pfirmann grading system.
The Oswestry disability index is a validated scale that measures functional disability in patients with spinal pain, and the EQ-5D is a breif questionnaire used to assess health related quality of life. Because serum periostin levels reflect the severity of IVDD, periostin may also influence patient's functional disability and quality of life. However, whether serum periostin concentration correlates with functional disability and quality of life has not yet been studied.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：JIHEE Hong
- 電話番号：01046794343
- メール：swon13@daum.net
研究場所
-
-
-
Daegu、韓国
- 募集
- Hong Ji Hee
-
コンタクト：
- Sungwon Jung
- メール：swon12@daum.net
-
コンタクト：
- JIHEE Hong, Professor
- 電話番号：01046794343
- メール：swon13@daum.net
-
-
Daegu
-
Daegu、Daegu、韓国、42601
- 募集
- Ji Hee
-
コンタクト：
- J Hee Hong
- 電話番号：01046794343
- メール：swon13@daum.net
-
コンタクト：
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- lumbar disc herniation
- lumbar spinal canal stenosis
- patients who have MRI
- patients who can fill in the ODI and EQ5D without other's help
Exclusion Criteria:
- allergic disease
- allergic rhinitis
- asthma
- atopic dermatitis
- chronic sinusitis
- history of cancer
- fracture within 6 months
- severe osteoporosis
- knee osteoarthritis
- hip osteoarthrtis
- spinal surgery within 6 months
- myocardiac infarction
- heart failure
- liver cirrhosis
- chronic kidney disease
- rhematoid disease
- systemic lupus erythematosus
- ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- systemic steroid user
- acute or chronic infection
- BMI > 30
- uncontrolled hypertension
- uncontrolled diabetes
- recent history of vaccination
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
back pain patient group
|
blood sampling to detect the level of periostin and cytokine
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Identifying the correlation of periostin level and ODI and EQ5D
時間枠：Day1
|
Day1
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Identifying the correlation of the periostin level and Cytokine level and Pfirmann grading
時間枠：Day1
|
Day1
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。